C4 Therapeutics (CCCC)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	58.94 mm	58.94 mm	58.94 mm	58.94 mm	58.94 mm	58.94 mm
Cash burn (monthly)	1.38 mm	5.92 mm	12.57 mm	9.97 mm	5.98 mm	5.43 mm
Cash used (since last report)	2.88 mm	12.32 mm	26.14 mm	20.73 mm	12.43 mm	11.29 mm
Cash remaining	56.06 mm	46.62 mm	32.80 mm	38.21 mm	46.51 mm	47.65 mm
Runway (months of cash)	40.5	7.9	2.6	3.8	7.8	8.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

CCCC institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	117	122	-4.1%
Opened positions	26	33	-21.2%
Closed positions	31	28	+10.7%
Increased positions	38	38	–
Reduced positions	33	30	+10.0%

13F shares	Current	Prev Q	Change
Total value	230.83 bn	359.98 bn	-35.9%
Total shares	76.56 mm	76.21 mm	+0.5%
Total puts	114.70 k	54.80 k	+109.3%
Total calls	651.30 k	669.50 k	-2.7%
Total put/call ratio	0.2	0.1	+115.2%

Largest owners	Shares	Value	Change
Soleus Capital Management	6.98 mm	$25.12 bn	+5.7%
Lynx1 Capital Management	6.85 mm	$24.67 bn	-0.4%
Soleus Capital Master Fund	6.60 mm	$36.52 mm	0.0%
Wasatch Advisors	6.07 mm	$21.86 bn	+7.0%
Betta Investment	5.57 mm	$35.30 mm	0.0%
BlackRock	5.56 mm	$20.01 bn	+13.7%
Ra Capital Management	4.88 mm	$17.56 bn	0.0%
Orbimed Advisors	4.38 mm	$15.76 bn	0.0%
MS Morgan Stanley	3.84 mm	$13.82 bn	+65.1%
Vanguard	3.35 mm	$12.05 bn	-0.7%

Largest transactions	Shares	Bought/sold	Change
Commodore Capital	0.00	-3.41 mm	EXIT
Samlyn Capital	3.02 mm	+3.02 mm	NEW
STT State Street	1.22 mm	-1.58 mm	-56.4%
MS Morgan Stanley	3.84 mm	+1.51 mm	+65.1%
Adage Capital Partners GP, L.L.C.	1.55 mm	+1.03 mm	+198.1%
Point72 Asset Management	196.47 k	-1.01 mm	-83.7%
BlackRock	5.56 mm	+667.92 k	+13.7%
UBS UBS	757.85 k	+423.77 k	+126.8%
Wasatch Advisors	6.07 mm	+395.23 k	+7.0%
Soleus Capital Management	6.98 mm	+374.95 k	+5.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CCCC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Feb 25	Hirsch Andrew	Common Stock	Payment of exercise	Dispose F	No	No	3.18	9,370	29.80 k	423,145
14 Feb 25	Paige Mahaney	Common Stock	Grant	Acquire A	No	No	0	28,200	0.00	105,000
14 Feb 25	Paige Mahaney	Stock Option Common Stock	Grant	Acquire A	No	No	3.18	42,400	134.83 k	42,400
14 Feb 25	Leonard Reyno	Common Stock	Payment of exercise	Dispose F	No	No	3.18	5,145	16.36 k	173,764
14 Feb 25	Leonard Reyno	Common Stock	Grant	Acquire A	No	No	0	87,100	0.00	178,909
14 Feb 25	Leonard Reyno	Stock Option Common Stock	Grant	Acquire A	No	No	3.18	130,600	415.31 k	130,600
14 Feb 25	Hirsch Andrew	Common Stock	Payment of exercise	Dispose F	No	No	3.18	12,847	40.85 k	432,515
14 Feb 25	Hirsch Andrew	Common Stock	Grant	Acquire A	No	No	0	223,500	0.00	445,362
14 Feb 25	Hirsch Andrew	Stock Option Common Stock	Grant	Acquire A	No	No	3.18	335,300	1.07 mm	335,300
14 Feb 25	Mark Mossler	Common Stock	Payment of exercise	Dispose F	No	No	3.18	1,586	5.04 k	18,204

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

AT&T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday

19 Dec 24

Wells Fargo Upgrades C4 Therapeutics to Overweight, Raises Price Target to $12

19 Dec 24

Wells Fargo analyst Derek Archila upgrades C4 Therapeutics (NASDAQ:CCCC) from Equal-Weight to Overweight and raises the price target from $8 to $12.

C4 Therapeutics Presented Cemsidomide Phase 1 Data At ASH Meeting; Said In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36% ORR, 45% CBR; In Non-Hodgkin's Lymphoma, Cemsidomide Monotherapy Demonstrated 38% ORR, 19% CMR

8 Dec 24

C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today presented clinical data from the ongoing Phase 1 trial of

Press releases

From Benzinga Pro

C4 Therapeutics to Participate in Upcoming March Investor Conferences

24 Feb 25

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

8 Dec 24

In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across